Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexicon Pharmaceuticals (LXRX) Operating Leases (2023 - 2024)

Lexicon Pharmaceuticals (LXRX) has disclosed Operating Leases for 2 consecutive years, with $6.4 million as the latest value for Q1 2024.

  • On a quarterly basis, Operating Leases changed N/A to $6.4 million in Q1 2024 year-over-year; TTM through Mar 2024 was $6.4 million, a N/A change, with the full-year FY2023 number at $5.3 million, changed N/A from a year prior.
  • Operating Leases was $6.4 million for Q1 2024 at Lexicon Pharmaceuticals, up from $5.3 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $6.4 million in Q1 2024 to a low of $5.3 million in Q4 2023.